View all dosages and compare prices:
Buy Retatrutide — all dosages →
Retatrutide 6 mg
PEN PEPTIDE · Triple agonist
Next-generation triple agonist · 6 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
6 mgRetatrutide 6 mg from PEN PEPTIDE — stabilized pen injector with triple agonist GLP-1/GIP/glucagon. 120 units of 50 mcg each. Starting dose for course initiation. MSSPT technology — stable formula.
Specialist support included in the price
A personal DOZA specialist guides you throughout the entire course — from first consultation to results.
Triple agonist — next generation
Retatrutide — a triple GLP-1/GIP/glucagon agonist. Investigational Phase 3 molecule by Eli Lilly. Not approved by FDA/EMA.
Manufacturer: PEN PEPTIDE
PEN PEPTIDE — a brand of peptide products.
Free consultation
Benefits
- ✓Triple mechanism of action — only agonist GLP-1 + GIP + glucagon
- ✓Starting dose — ideal for course initiation (6 mg = 3 doses of 2 mg)
- ✓Pre-Mixed stabilized pen — ready solution, no reconstitution needed
- ✓MSSPT technology — tolerant to short-term temperature fluctuations
- ✓Purity ≥98% — GMP-certified production in Europe
- ✓Up to 24% weight loss over 48 weeks (Phase 2 study, NEJM 2023)
- ✓Delivery in thermal box with cold elements (2–8°C) across Ukraine
Retatrutide 6 mg (PEN PEPTIDE) — detailed description
Retatrutide 6 mg from PEN PEPTIDE — triple agonist of GLP-1, GIP and glucagon receptors in a stabilized pen injector.
The 6 mg pen contains 120 units of 50 mcg each. Dosage table:
• 1 unit = 50 mcg
• 20 units = 1 mg
• 40 units = 2 mg
Ideal for starting a course — allows precise dosing of the starting 2 mg dose and gradual titration.
Formula stabilized using MSSPT (Molecular Structure Stabilization Process Technology) — maintains structural integrity and bioactivity even with temporary temperature deviations above 8°C during transportation.
Purity ≥98%. Manufactured in certified GMP laboratories in Europe.
How it works — mechanism of action
Retatrutide — the only triple agonist GLP-1 + GIP + glucagon. Acts on three receptors simultaneously:
1. GLP-1 — reduces appetite, slows gastric emptying, regulates glucose levels.
2. GIP — enhances GLP-1 effects and improves fat tissue metabolism.
3. Glucagon — activates lipolysis (fat breakdown) and thermogenesis (calorie burning).
In the Phase 2 clinical trial (NEJM, 2023), participants on 12 mg dose lost up to 24% body weight over 48 weeks — the best result among all weight loss medications.
Dosage
Standard starting dose: 2 mg once weekly subcutaneously.
Gradual titration: 2 mg → 4 mg → 6 mg → 8 mg depending on tolerability and results.
Subcutaneous injection in abdomen, thigh or shoulder area. Same day of the week.
Do not increase dose until appetite returns. Maintain balanced nutrition.
What's in the kit
Стабілізована шприц-ручка PEN PEPTIDE Retatrutide 6 мг.
• 1 ручка = 6 мг ретатрутиду (120 юнітів × 50 мкг)
• 1 юніт = 50 мкг, 20 юнітів = 1 мг, 40 юнітів = 2 мг
• Pre-Mixed — готовий розчин, не потребує розведення
• Технологія MSSPT — стабілізована формула
• Чистота ≥98%
Composition
Діюча речовина: ретатрутид (retatrutide) 6 мг загалом у ручці (120 юнітів × 50 мкг).
Стабілізована формула (MSSPT — Molecular Structure Stabilization Process Technology):
• Оптимізовані буферні компоненти для підтримки стабільного pH
• Антиоксиданти для запобігання окислювальній деградації
• Стабілізуючі агенти для запобігання агрегації
Чистота ≥98%. Вироблено на GMP-сертифікованих лабораторіях.
Storage
Зберігати в холодильнику при температурі 2–8°C. Не заморожувати.
Стабілізована формула (MSSPT) — толерантна до короткочасних відхилень температури вище 8°C під час транспортування.
Зберігати ручку в оригінальній упаковці для захисту від світла.
Після першого використання — зберігати при 2–8°C, використати протягом терміну придатності.
Не зберігати з приєднаною голкою.
Тільки для підшкірного введення.
Клінічні дослідження
Retatrutide (LY3437943 6 mg) — потрійний агоніст GLP-1 + GIP + глюкагон Eli Lilly. Phase 3 (TRIUMPH-1, TRIUMPH-2). Очікуване схвалення FDA — 2026–2027. На /research зібрана уся доказова база Phase 2 та статус trials.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (NEJM 2023)PubMed · 2023
- TRIUMPH-1: Phase 3 study of LY3437943 in adults with obesityClinicalTrials.gov · 2024
Retatrutide is an investigational drug currently in Phase 3 clinical trials. Not approved by FDA, EMA or МОЗ України as of 2026.
View full клінічні дослідження database →Titration protocol to 6 mg (retatrutide (triple GLP-1 / GIP / glucagon agonist))
Starting dose (Phase 3 TRIUMPH)
First increase
Second increase
Maximum studied dose
Injection once weekly (per study protocol), subcutaneous (abdomen, thigh or upper arm). Expected weight loss at 6 mg: ~24% over 48 weeks (Phase 2) (based on clinical studies).
Who is Retatrutide 6 mg for
- Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA
- Triple GLP-1 / GIP / glucagon agonist — a unique mechanism of action
- For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect
- Strictly under medical supervision
Retatrutide 6 mg — compared to other doses
- Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023)
- Compared to Mounjaro 15 mg (~22–26%) — a similar effect, but with a triple mechanism
- Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure
- No final Phase 3 results yet — efficacy and safety are still being confirmed
FAQ about Retatrutide 6 mg (PEN PEPTIDE)
You can buy Retatrutide 6 mg PEN PEPTIDE at DOZA — specialized online service. Orders are placed through the website cart or Telegram. Delivery across Ukraine with cold chain compliance 2–8°C.
Anastasia Shapoval
Metabolic Programs and Weight Control Specialist
Other Retatrutide dosages
DOZA client reviews for Retatrutide 6 mg (PEN PEPTIDE)
Retatrutide 6 mg (PEN PEPTIDE) — noticeable results in just 3 weeks. Cold chain delivery, everything neat. Thank you, DOZA!
Ordering Retatrutide 6 mg (PEN PEPTIDE) via DOZA — fast delivery across Ukraine. Consultant helped choose the right dose. Triple agonist works more effectively.
All client results →
Before/after photos · numbers · timelines · reviews
Other Retatrutide dosages
Buy Retatrutide 6 mg in Ukraine
Buy Retatrutide 6 mg (PEN PEPTIDE) — next-generation triple GLP-1/GIP/glucagon agonist from DOZA. Next-generation triple agonist · 6 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE. Dosage 6 mg — for optimal therapeutic effect. Order via DOZA online service, delivery 1–2 days.
Free DOZA specialist consultation. Available 24/7.
Buy Retatrutide 6 mg (PEN PEPTIDE) in Ukraine — DOZA online service with delivery in 1–2 days. Specialist consultation included.
⚠️ Retatrutide is an investigational product currently undergoing Phase 3 clinical trials. Results may vary. Consult a specialist before starting the program. Retatrutide is currently undergoing large-scale Phase 3 clinical trials (the TRIUMPH program). Final regulatory approval is expected after the completion of trials.